{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:56:23Z","timestamp":1781686583334,"version":"3.54.5"},"reference-count":14,"publisher":"Norwegian Medical Association","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.21.0503","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T03:21:18Z","timestamp":1631071278000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunterapi ved malignt pleuralt mesoteliom"],"prefix":"10.4045","volume":"141","author":[{"given":"Saima Jamil","family":"Farooqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-9064","authenticated-orcid":false,"given":"Maria Moksnes","family":"Bjaan\u00e6s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5slaug","family":"Helland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-3628","authenticated-orcid":false,"given":"Vilde Drageset","family":"Haakensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Viscardi\u00a0G, Di Liello\u00a0R, Morgillo\u00a0F. How I treat malignant pleural mesothelioma. ESMO Open 2020; 4 (suppl 2): e000669. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32156681&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fesmoopen-2019-000669","DOI":"10.1136\/esmoopen-2019-000669"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Cantini\u00a0L, Hassan\u00a0R, Sterman\u00a0DH et al. Emerging treatments for malignant pleural mesothelioma: Where are we heading? Front Oncol 2020; 10: 343. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32226777&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffonc.2020.00343","DOI":"10.3389\/fonc.2020.00343"},{"key":"ref=3","unstructured":"Kreftregisteret. Statistikkbank. https:\/\/sb.kreftregisteret.no\/insidens Lest 23.7.2021."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Testa\u00a0JR, Cheung\u00a0M, Pei\u00a0J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022\u20135. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21874000&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fng.912","DOI":"10.1038\/ng.912"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Guo\u00a0G, Chmielecki\u00a0J, Goparaju\u00a0C et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015; 75: 264\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25488749&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1158%2F0008-5472.CAN-14-1008","DOI":"10.1158\/0008-5472.CAN-14-1008"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Bovolato\u00a0P, Casadio\u00a0C, Bill\u00e8\u00a0A et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014; 9: 390\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24518090&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FJTO.0000000000000064","DOI":"10.1097\/JTO.0000000000000064"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Nakamura\u00a0A, Takuwa\u00a0T, Hashimoto\u00a0M et al. Clinical outcomes with recurrence after pleurectomy\/decortication for malignant pleural mesothelioma. Ann Thorac Surg 2020; 109: 1537\u201343. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31962118&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.athoracsur.2019.11.048","DOI":"10.1016\/j.athoracsur.2019.11.048"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Ellis\u00a0P, Davies\u00a0AM, Evans\u00a0WK et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006; 1: 591\u2013601. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17409924&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1556-0864(15)30366-X","DOI":"10.1016\/S1556-0864(15)30366-X"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Vogelzang\u00a0NJ, Rusthoven\u00a0JJ, Symanowski\u00a0J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636\u201344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12860938&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2003.11.136","DOI":"10.1200\/JCO.2003.11.136"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Eberst\u00a0G, Anota\u00a0A, Scherpereel\u00a0A et al. Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase iii trial. Clin Cancer Res 2019; 25: 5759\u201365. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31175096&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1158%2F1078-0432.CCR-18-2860","DOI":"10.1158\/1078-0432.CCR-18-2860"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"de Gooijer\u00a0CJ, Borm\u00a0FJ, Scherpereel\u00a0A et al. Immunotherapy in malignant pleural mesothelioma. Front Oncol 2020; 10: 187. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32154179&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffonc.2020.00187","DOI":"10.3389\/fonc.2020.00187"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Baas\u00a0P, Scherpereel\u00a0A, Nowak\u00a0AK et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375\u201386. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33485464&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(20)32714-8","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Gray\u00a0SG, Mutti\u00a0L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res 2020; 9 (suppl 1): S100\u201319. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32206576&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.21037%2Ftlcr.2019.11.23","DOI":"10.21037\/tlcr.2019.11.23"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Haakensen\u00a0VD, Nowak\u00a0AK, Ellingsen\u00a0EB et al. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med 2021; 19: 232. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34059094&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12967-021-02905-3","DOI":"10.1186\/s12967-021-02905-3"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:15:42Z","timestamp":1781684142000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2021\/09\/kronikk\/immunterapi-ved-malignt-pleuralt-mesoteliom"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,7]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.21.0503","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}